Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement ...

Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for Ozempic, have reached a settlement in the US ...

Shares of Natco Pharma Ltd surged nearly 4.35 per cent to Rs 1,413.45 on Monday, commanding a total market capitalization ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Ahead of the market opening on Wednesday, Axis Direct picked five stocks that can generate profits in 5 to 15 days. These are ...

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

The strong up move was seen in the stock price with the scrip touching the day's high of Rs 1,408.70 per share on the NSE, ...

Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding ...

Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.